Approval · Notice of Compliance 18844 · 2017
CARDIOLITE: Notice of Compliance 18844
Issued January 9, 2017
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 18844
- Date
- January 9, 2017
- Company
- Lantheus Mi Canada IncMontreal, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New manufacturing facility
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CARDIOLITE | Not yet assigned | — |
Medicinal ingredients
- TETRAKIS [CU(MIB)4]BF4 1 MG per VIAL